The opening salvo in what promises to be one of the hottest debates in the new Congress was fired January 29 during a day-long hearing in the House Committee on Oversight and Reform—how to lower the price of prescription drugs. And it didn’t take long to make it clear that patents are right in the middle of the scrum. The role of patents was a prominent part of the House hearing. While cursory nods were made to the importance of encouraging innovation, the witnesses discussed how patent exclusivity, thickets, and evergreening drove up prices while promoting the greater use of Patent Trial and Appeal Board (PTAB) reviews against drug patents. The Committee was assured that curtailing patents wouldn’t harm innovation because the National Institutes of Health (NIH) is such an important funder of life science R&D.
The post Patents in the Crosshairs During House Drug Pricing Debate appeared first on IPWatchdog.com | Patents & Patent Law.
Business
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- Trade and Commerce in West Africa and How it Influences IP Rights
- Supreme Court Ponders Proper Application of the Computer Fraud and Abuse Act
- How Patents Helped Sprout the World’s First Plantable Pencil
- Patent Filings Roundup: Battle-Tested Off-Roading Patent Asserted; Jack Henry Battered Again
Recent Posts
- US Inventor Backs SCOTUS Petition to Clarify Claim Construction Principles
- Iancu Says Goodbye, Urges Commitment to ‘American Innovation Renaissance’
- Biden’s Opportunity to Protect American Innovation
- Washington Insiders Say Farewell to 2020 and Look Ahead to 2021
- Innovation Alliance Urges Biden Administration to Support Patent Rights